Kidney Cancer Treatment: Which Option Fits Your Case?

A kidney cancer diagnosis often comes with more than one treatment recommendation. That can feel confusing, especially when different specialists suggest different paths. The right kidney cancer treatment depends on factors specific to you: how far the cancer has spread, your age and overall health, how much kidney function you want to preserve, and your own goals for recovery. This article explains the main options - surgery, targeted therapy, and immunotherapy - so you can discuss them with your doctor.

What Are the Main Kidney Cancer Treatment Options?

Most kidney cancers are a type called renal cell carcinoma, or RCC. According to the National Cancer Institute's patient guide to kidney cancer treatment, the main options include surgery, targeted therapy, immunotherapy, arterial embolization, and for some small tumors, active surveillance. Radiation therapy is used in specific situations, such as easing pain from cancer that has spread to bone.

Which option - or combination of options - makes sense for you depends almost entirely on the stage of your cancer at diagnosis and your broader health profile. The sections below cover each approach in turn.

Surgery for Kidney Cancer: Partial or Radical Nephrectomy?

Surgery is the primary treatment for most kidney cancers that have not spread beyond the kidney. Two types of kidney removal, called nephrectomy, are commonly used:

• Partial nephrectomy: The surgeon removes the tumor and a small margin of healthy tissue, leaving the rest of the kidney in place. This is generally preferred for smaller tumors because it protects long-term kidney function.
• Radical nephrectomy: The entire kidney is removed, sometimes along with surrounding fat, the adrenal gland above the kidney, and nearby lymph nodes. This may be needed for larger or more complex tumors.

Both procedures can be done as open surgery or using minimally invasive methods - laparoscopic or robotic-assisted techniques - which typically mean shorter hospital stays and a faster return to daily activities. The best approach depends on tumor size and position, the health of your remaining kidney, and the experience of your surgical team.

Preserving kidney function matters beyond cancer control. People with significantly reduced kidney function have higher risks of certain heart and blood vessel problems over time. For that reason, many urologic oncologists try to spare as much healthy kidney tissue as safely possible. Keeping even part of the kidney helps your long-term health.

For some Stage III tumors that have grown into the main vein or spread to nearby lymph nodes, a more extensive operation may be necessary. Your surgeon will explain what that involves and what recovery typically looks like.

How Does Kidney Cancer Stage Guide the Decision?

Stage is the single biggest driver of the treatment your oncologist will recommend. The National Cancer Institute SEER database reports that the 5-year relative survival rate for localized kidney cancer - cancer that has not spread beyond the kidney - is approximately 93%. That figure drops significantly when the disease has reached distant sites, which is why staging is done carefully and early.

• Stage I and II (localized): Surgery is the standard first-line treatment. Partial nephrectomy is preferred where it is technically possible.
• Stage III (locally advanced): Surgery remains central, but your team may discuss whether targeted drugs or immunotherapy are appropriate before or after the operation.
• Stage IV (metastatic): Targeted therapy and immunotherapy become the primary tools, often used in combination. Surgery may still have a role in certain carefully selected situations.

If you are still working to understand what your stage means for your care, our plain-language guide to how cancer staging works walks through the core framework - the same principles apply across cancer types.

How Do Surgery, Targeted Therapy, and Immunotherapy Compare for Kidney Cancer?

Sources: NCI kidney cancer treatment guide; American Cancer Society targeted therapy overview; American Cancer Society treatment by stage.

The table makes clear that the choice between these approaches is less about which is inherently "better" and more about which fits your specific situation. Surgery and systemic therapy are not always in competition - they are frequently used in sequence or, for certain advanced cancers, in combination. The best plan is the one built around your tumor's biology, your stage, and your health goals.

Targeted Therapy: Blocking Cancer's Growth Signals

Targeted drugs for kidney cancer work by interfering with specific proteins that cancer cells use to grow and form new blood vessels. Most of the targeted drugs used in RCC block a family of proteins called tyrosine kinases. Because of this, they are known as TKIs, short for tyrosine kinase inhibitors. The American Cancer Society's overview of targeted therapy for kidney cancer explains how these drugs work.

Targeted therapy is taken as a daily pill. Many people manage treatment from home and come in for regular lab work and clinic reviews. Side effects can include high blood pressure, fatigue, diarrhea, and a skin reaction called hand-foot syndrome that causes soreness and redness on the palms and soles. These effects vary from person to person and from drug to drug.

Different drugs in the TKI class have different benefit and side-effect profiles, and the order in which they are used matters too. A second specialist may have a more nuanced view of the best starting drug for your specific case and what the sequencing plan should look like if the first drug stops working.

If your oncologist has mentioned biomarker testing or molecular profiling alongside a targeted therapy recommendation, our article on what your tumor's molecular profile means for treatment explains what those results typically change about the treatment plan.

Immunotherapy: Helping Your Immune System Fight Back

Immunotherapy drugs for kidney cancer work by removing a "brake" that cancer cells use to hide from your immune system. Once that brake is released, immune cells are better able to find and attack cancer cells. These drugs are called checkpoint inhibitors, and they are now a core part of treatment for advanced kidney cancer.

For metastatic kidney cancer, checkpoint inhibitors are often used in combination - either with each other or alongside a targeted drug. Research has shown that certain combinations may improve outcomes compared to targeted therapy alone. In 2024, the NCI reported that one checkpoint inhibitor, when given after surgery for certain high-risk kidney cancers, was associated with improved survival compared with placebo. That finding is summarized on the NCI website.

Immunotherapy is given by IV infusion at an outpatient clinic, typically every two to six weeks depending on the drug and regimen. Because these drugs activate the immune system broadly, they can sometimes cause immune-related side effects - such as inflammation in the lungs, liver, bowel, or thyroid - that need prompt medical attention. Your care team will monitor for these throughout treatment.

Eligibility for specific immunotherapy combinations depends on your risk category (a clinical scoring system your oncologist uses), your kidney function, and other health conditions. This is an area where treatment guidelines have shifted quickly over the past several years. A second opinion from a kidney cancer specialist may surface combinations or sequencing options your current team has not yet prioritized.

When Might Active Surveillance Be an Option?

Not every kidney tumor requires immediate treatment. For very small kidney masses - often found by accident on a scan done for another reason - active surveillance may be appropriate. This means regular imaging, usually every few months at first, to track whether the mass grows or changes. No surgery or systemic therapy is started unless specific thresholds are met.

Active surveillance tends to be discussed for older adults, for patients with other significant health conditions that raise surgical risk, and for tumors that appear slow-growing on imaging. It is not a passive choice. It requires a structured follow-up schedule and a clear, shared understanding with your doctor about when switching to active treatment becomes necessary.

If a small mass was found incidentally on your scan and surveillance has been offered as one option, consulting a urologic oncologist who specializes in kidney cancer can help you feel confident that the monitoring plan is thorough and that nothing is being overlooked.

Should You Get a Second Opinion Before Deciding?

Kidney cancer treatment - particularly for advanced disease - has changed significantly over the past decade. Guidelines from major bodies such as the National Comprehensive Cancer Network are updated regularly as new trial data comes out. The treatment sequence recommended in 2018 or 2019 may not match what leading centers recommend today, especially regarding how targeted drugs and immunotherapy combinations are ordered and combined.

A second opinion is a normal and healthy step. It is not a vote of no confidence in your current doctor - it is a way of confirming that the full range of options has been considered for your specific case. This matters most at Stage III or IV, when you have an unusual tumor subtype, or when you feel uncertain or rushed.

An online oncology consultation lets you share your scans, pathology report, and lab results with a verified specialist from home - no travel required, and often with a written review available within 48 hours. Our guide to choosing between a local oncologist, an online second opinion, and care abroad can help you think through the practical options before you decide.

When you are ready to speak with a specialist, you can upload your reports and connect with a verified oncologist through HealthUnwired - video consultations are available within 48 hours, with no travel needed.

When to Talk to Your Doctor

Reach out to your oncologist or urologist promptly if:

• You have received a kidney cancer diagnosis and have not yet discussed all available treatment approaches.
• You feel uncertain about a recommendation for surgery, targeted therapy, immunotherapy, or the sequence of treatments.
• A kidney mass was found incidentally and you want to understand whether active surveillance or treatment is more appropriate for your situation.
• Your cancer has progressed or recurred and you want to know what the next step looks like.
• You have existing kidney disease, only one functional kidney, or other health conditions that may affect which treatment is safest for you.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.